Evidence map›Paper›PMID 32443847›Full record

ArticleCancers2020

A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma.

Toshio Fujisawa, Takeshi Shimamura, Kaku Goto, Ryo Nakagawa, Ryosuke Muroyama, Yoshinori Ino, Hajime Horiuchi, Itaru Endo, Shin Maeda, Yasushi Harihara and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease.The Journal of allergy and clinical immunology · 2022
    Review
  5. Review
  6. Review
  7. Modeling pancreatic cancer in mice for experimental therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2021
    Review
  8. Review
  9. Article
  10. Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Toshio FujisawaDepartment of Gastroenterology, Juntendo University, Tokyo 113-8421, Japan.
Takeshi ShimamuraDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
Kaku GotoDivision of Advanced Genome Medicine, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Ryo NakagawaDivision of Advanced Genome Medicine, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Ryosuke MuroyamaDivision of Advanced Genome Medicine, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Yoshinori InoPathology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Hajime HoriuchiDepartment of Pathology, NTT Medical Center, Tokyo 141-0022, Japan.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
Shin MaedaDepartment of Gastroenterology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
Yasushi HariharaDepartment of Surgery, NTT Medical Center, Tokyo 141-0022, Japan.
Atsushi NakajimaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.ORCID 0000-0002-6263-1436
Nobuyuki MatsuhashiDepartment of Gastroenterology, NTT Medical Center, Tokyo 141-0022, Japan.ORCID 0000-0002-0139-430X
Naoya KatoDivision of Advanced Genome Medicine, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hiroyuki IsayamaDepartment of Gastroenterology, Juntendo University, Tokyo 113-8421, Japan.
Ankit PuriTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Akiko SuzukiTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Ian BellayrTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Pamela LelandTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Bharat H JoshiTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0001-5246-3881
Raj K PuriTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Center for Biologics Evaluation and Research · USThe University of Tokyo · JPYokohama City University · JPNTT Medical Center · JPJuntendo University · JP

Funding

JSPS KAKENHI JP18K07332
6 · The paper itself

Abstract

Perineural invasion (PNI) is one of the major pathological characteristics of pancreatic ductal adeno-carcinoma (PDAC), which is mediated by invading cancer cells into nerve cells. Herein, we identify the overexpression of Interleukin-13 Receptor alpha2 (IL-13Rα2) in the PNI from 236 PDAC samples by studying its expression at the protein levels by immunohistochemistry (IHC) and the RNA level by in situ hybridization (ISH). We observe that ≥75% samples overexpressed IL-13Rα2 by IHC and ISH in grade 2 and 3 tumors, while ≥64% stage II and III tumors overexpressed IL-13Rα2 (≥2+). Interestingly, ≥36 % peripancreatic neural plexus (PL) and ≥70% nerve endings (Ne) among PNI in PDAC samples showed higher levels of IL-13Rα2 (≥2+). IL-13Rα2 +ve PL and Ne subjects survived significantly less than IL-13Rα2 -ve subjects, suggesting that IL-13Rα2 may have a unique role as a biomarker of PNI-aggressiveness. Importantly, IL-13Rα2 may be a therapeutic target for intervention, which might not only prolong patient survival but also help alleviate pain attributed to perineural invasion. Our study uncovers a novel role of IL-13Rα2 in PNI as a key factor of the disease severity, thus revealing a therapeutically targetable option for PDAC and to facilitate PNI-associated pain management.

Indexed as

IL-13Rα2pancreatic ductal adenocarcinomaperineural invasionprognosis

Identifiers

PMID32443847
PMCPMC7281570
OpenAlexW3027556558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.